Overview

AST-021p Study in Advanced Solid Tumors

Status:
Recruiting

Trial end date:
2023-02-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety, tolerability and optimal Immunogenic dose of therapeutic cancer vaccine (AST-021p) in patients With advanced solid tumors A phase 1 study

Phase:

Phase 1

Details

Lead Sponsor:

Aston Sci. Co., Ltd.